Literature DB >> 11908557

The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis.

Patrick H Dessein1, Barry I Joffe, Anne Stanwix, Andre S Botha, Zubair Moomal.   

Abstract

OBJECTIVE: Rheumatoid arthritis (RA) is associated with an increased mortality rate from cardiovascular disease. This may relate to insulin resistance and dyslipidemia, which were both reported to correlate with the acute phase response in RA. We investigated whether insulin resistance and dyslipidemia could be explained by the acute phase response as well as excess weight in inflammatory arthritis.
METHODS: We investigated 87 patients, 38 with RA, 29 with spondyloarthropathy, 20 with undifferentiated inflammatory arthritis. Thirty age, sex, and race matched healthy volunteers served as controls. Fasting blood samples were taken for determination of erythrocyte sedimentation rate (ESR), plasma glucose, serum insulin, and total cholesterol (chol), low density lipoprotein cholesterol (LDL-chol), high density lipoprotein cholesterol (HDL-chol), and triglycerides. Insulin resistance was estimated by the homeostasis model assessment for insulin resistance (HOMA) and the quantitative insulin sensitivity check index (QUICKI).
RESULTS: In controls the mean (SD) HOMA (microU x mmol/ml x l), QUICKI, body mass index (BMI, kg/m2), and ESR (mm/h) were 1.1 (0.5), 0.393 (0.048), 22.9 (2.8), and 13 (8) in patients; they were 1.9 (1.3), 0.357 (0.037), 26.5 (4.2), and 26 (18) in controls, respectively. Each of these differences was highly significant (p < 0.001). HDL-chol concentrations were lower (p = 0.002) and chol/HDL-chol ratios and triglyceride levels were higher (p < 0.001 and p = 0.004, respectively) in patients compared to controls. A high ESR predicted insulin resistance and dyslipidemia, while a high BMI similarly predicted insulin resistance but not dyslipidemia. After controlling for ESR and BMI, insulin sensitivity was no longer different between patients and controls, while HDL-chol concentrations remained lower (p = 0.015) and chol/HDL-chol ratios remained higher (p = 0.003) in patients compared to controls.
CONCLUSION: Insulin resistance and dyslipidemia were highly prevalent in patients with inflammatory arthritis. The acute phase response and excess weight could fully explain the insulin resistance but only partially explain the dyslipidemia. These findings have important implications for the management of inflammatory arthritis.

Entities:  

Mesh:

Year:  2002        PMID: 11908557

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

1.  Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study.

Authors:  S A Karvounaris; P I Sidiropoulos; J A Papadakis; E K Spanakis; G K Bertsias; H D Kritikos; E S Ganotakis; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

2.  High prevalence of metabolic syndrome in patients with ankylosing spondylitis.

Authors:  Domenico Malesci; Alferio Niglio; Gianna Angela Mennillo; Rosario Buono; Gabriele Valentini; Giovanni La Montagna
Journal:  Clin Rheumatol       Date:  2006-08-25       Impact factor: 2.980

3.  Anti-arthritogenic and cardioprotective action of hesperidin and daidzein in collagen-induced rheumatoid arthritis.

Authors:  Shafeeque Ahmad; Khursheed Alam; M Mobarak Hossain; Mahino Fatima; Fakiha Firdaus; Mohammad Faraz Zafeer; Zarina Arif; Murad Ahmed; K A Nafees
Journal:  Mol Cell Biochem       Date:  2016-10-04       Impact factor: 3.396

Review 4.  Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment.

Authors:  Mariana J Kaplan
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

5.  [Multimorbidity in elderly rheumatic patients part 2].

Authors:  H-J Lakomek; T Brabant; M Lakomek; D Lüttje
Journal:  Z Rheumatol       Date:  2013-08       Impact factor: 1.372

6.  Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study.

Authors:  Carlos Lorenzo; Anthony J Hanley; Steven M Haffner
Journal:  Diabetologia       Date:  2013-10-19       Impact factor: 10.122

Review 7.  Rheumatoid arthritis and cardiovascular disease: an update on treatment issues.

Authors:  Medha Barbhaiya; Daniel H Solomon
Journal:  Curr Opin Rheumatol       Date:  2013-05       Impact factor: 5.006

Review 8.  Atherosclerotic cardiovascular disease in rheumatoid arthritis.

Authors:  Inmaculada del Rincón; Agustín Escalante
Journal:  Curr Rheumatol Rep       Date:  2003-08       Impact factor: 4.592

Review 9.  Management of cardiovascular disease risk in chronic inflammatory disorders.

Authors:  Mariana J Kaplan
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

10.  Impaired beta cell function is present in nondiabetic rheumatoid arthritis patients.

Authors:  Iván Ferraz-Amaro; Jose A García-Dopico; Lilian Medina-Vega; Miguel A González-Gay; Federico Díaz-González
Journal:  Arthritis Res Ther       Date:  2013-01-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.